

Research

Open Access

Expression of human α_1 -proteinase inhibitor in *Aspergillus niger*

Elena Karnaukhova*¹, Yakir Ophir¹, Loc Trinh², Nimish Dalal², Peter J Punt³, Basil Golding¹ and Joseph Shiloach²

Address: ¹Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, 20892 USA, ²National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, 20892 USA and ³Department of Microbiology, TNO Quality of Life, 3704 HE Zeist, the Netherlands

Email: Elena Karnaukhova* - elena.karnaukhova@fda.hhs.gov; Yakir Ophir - ophiryakir@yahoo.com; Loc Trinh - loct@intra.niddk.nih.gov; Nimish Dalal - nimish.dalal@bms.com; Peter J Punt - peter.punt@tno.nl; Basil Golding - basil.golding@fda.hhs.gov; Joseph Shiloach - ljs@helix.nih.gov

* Corresponding author

Published: 29 October 2007

Received: 9 August 2007

Microbial Cell Factories 2007, **6**:34 doi:10.1186/1475-2859-6-34

Accepted: 29 October 2007

This article is available from: <http://www.microbialcellfactories.com/content/6/1/34>

© 2007 Karnaukhova et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Human α_1 -proteinase inhibitor (α_1 -PI), also known as antitrypsin, is the most abundant serine protease inhibitor (serpin) in plasma. Its deficiency is associated with development of progressive, ultimately fatal emphysema. Currently in the United States, α_1 -PI is available for replacement therapy as an FDA licensed plasma-derived (pd) product. However, the plasma source itself is limited; moreover, even with efficient viral inactivation steps used in manufacture of plasma products, the risk of contamination from emerging viruses may still exist. Therefore, recombinant α_1 -PI (r- α_1 -PI) could provide an attractive alternative. Although r- α_1 -PI has been produced in several hosts, protein stability in vitro and rapid clearance from the circulation have been major issues, primarily due to absent or altered glycosylation.

Results: We have explored the possibility of expressing the gene for human α_1 -PI in the filamentous fungus *Aspergillus niger* (*A. niger*), a system reported to be capable of providing more "mammalian-like" glycosylation patterns to secretable proteins than commonly used yeast hosts. Our expression strategy was based on fusion of α_1 -PI with a strongly expressed, secreted leader protein (glucoamylase G2), separated by dibasic processing site (N-V-I-S-K-R) that provides *in vivo* cleavage. SDS-PAGE, Western blot, ELISA, and α_1 -PI activity assays enabled us to select the transformant(s) secreting a biologically active glycosylated r- α_1 -PI with yields of up to 12 mg/L. Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) analysis further confirmed that molecular mass of the r- α_1 -PI was similar to that of the pd- α_1 -PI. *In vitro* stability of the r- α_1 -PI from *A. niger* was tested in comparison with pd- α_1 -PI reference and non-glycosylated human r- α_1 -PI from *E. coli*.

Conclusion: We examined the suitability of the filamentous fungus *A. niger* for the expression of the human gene for α_1 -PI, a medium size glycoprotein of high therapeutic value. The heterologous expression of the human gene for α_1 -PI in *A. niger* was successfully achieved to produce the secreted mature human r- α_1 -PI in *A. niger* as a biologically active glycosylated protein with improved stability and with yields of up to 12 mg/L in shake-flask growth.

Background

Human α_1 -PI is a well-characterized serpin (for recent reviews see [1-4]). Its best known physiological role is the inhibition of neutrophil elastase in the lungs. α_1 -PI is an abundant protease inhibitor in human plasma with a concentration range from 1.04 to 2.76 g/L in healthy individuals and with a half-life of 4–5 days in circulation [5-7]. As a result of a single mutation, α_1 -PI (Z-form) undergoes polymerization and accumulates in the liver, causing a deficiency of α_1 -PI in the blood that may result in progressive, ultimately fatal, emphysema [7].

α_1 -PI is a ~51 kDa single-chain glycoprotein (394 amino acid residues, 12% carbohydrates). It has a typical serpin secondary structure, featuring 9 α -helices, 3 β -sheets and a reactive center loop that is exposed for interaction with a target protease (e.g., review [3]).

Human pd- α_1 -PI is an FDA licensed product, used for replacement therapy in patients with hereditary α_1 -PI deficiency. However, the plasma source itself is limited; moreover, even with testing source material for relevant pathogenic viruses and robust viral clearance steps in the manufacturing process of plasma products, a risk from emerging and yet unknown viruses still remains. As an alternative, and in addition to plasma-derived products, the recombinant versions of α_1 -PI have been under intensive investigation. Since the early 1980s, the human gene for α_1 -PI has been expressed in various hosts, including *E. coli*, yeasts, insect cells, CHO cells, as well as in transgenic plants and animals (see recent review [8]).

We consider the filamentous fungi as a very attractive host for production of human α_1 -PI and other proteins of biomedical interest. The filamentous fungi systems offer various post-translational modifications to proteins, including glycosylation with the patterns that are more similar to those of mammals than glycosylation provided by common yeast hosts [9-11]. Although these systems have been used for commercial production of enzymes, very few human genes have been expressed in the filamentous fungi [12,13]. Protein size, glycosylation and metastable inhibitory nature of α_1 -PI represent the challenges in this multi-step work in view of an exclusive therapeutic importance of this inhibitor. Moreover, it is worthwhile to mention that multiple efforts of more than 20 years development still did not bring any recombinant α_1 -PI product to the market [8].

The most efficient strategy for expression of mammalian heterologous genes in fungi is a production of the target protein as a fusion protein linked to the C-terminus of a highly expressed and well secreted native fungal protein [14-16]. To release the target protein from the fusion chimera, the *in vivo* cleavage is accomplished by introducing

the KEX2-type protease recognition site at the fusion junction [17-20].

In the present study we examined the suitability of filamentous fungus *A. niger* for the expression of the human gene for α_1 -PI. We successfully achieved heterologous expression of the gene for α_1 -PI in *A. niger* to produce the secreted mature human r- α_1 -PI as a biologically active glycosylated protein with improved stability and with yields of up to 12 mg/L in shake-flask growth.

Results

1. Expression vector, transformation and selection

The expression cassette of pAN56-1/ α_1 -PI (Fig. 1) was constructed as described in Methods. The correct insertion of α_1 -PI was verified by restriction digest and DNA sequence analysis. Co-transformation of the protoplasts of *A. niger* strain D15#26 with pAN56-1/ α_1 -PI and pBLUE-AmdSPyrG (further referred as PyrG), followed by the selection on uridine-deficient media enabled us to isolate the transformants containing the selection fragment. Further screening for α_1 -PI production was performed by direct detection of the secreted target protein in the supernatants of shake-flask cultures.

2. Evaluation of proteolytic digestion by fungal proteases

Initially, the *A. niger* strain AB4-1 was used as the parental host strain for transformation. However, during the screening for r- α_1 -PI in shake-flask cultures we were unable to detect the target protein in the supernatants from the selected transformants. No band was seen on Western blots at the electrophoretic mobility of the standard pd- α_1 -PI, thus suggesting that either the transformants contained only the PyrG plasmid, but not the expression vector, or that the target protein is not visible because of proteolysis with native fungal proteases. This prompted us to evaluate the possibility that α_1 -PI might be proteolytically digested under the conditions of shake-flask growth. Given this reasoning, a protease-deficient host strain, D15#26, was chosen that resulted in successfully produced amounts of r- α_1 -PI. (However, several other effects, such as the efficiency of transcription from the sites of random integration in different transformants, or differences in the gene copy number between strains (not pursued in this study) may also result in significant differences in expression levels.)

Fig. 2 shows the results of the basic experiment conducted with standard pd- α_1 -PI, which was spiked with supernatant from 5 days growth of parental *A. niger* strain AB4-1 transformed with PyrG plasmid only. Whereas standard α_1 -PI in Tris buffer, pH 8.4 used as a control, was stable during the time of the experiment (10 h) both at 4 °C and RT, the same amounts of α_1 -PI spiked with supernatant of *A. niger* growth (naturally acidified during growth to pH




Figure 1

Diagram of the fusion region between glucoamylase (GLA) and α_1 -PI coding region (A1-PI) within the pAN56-1 expression vector showing the KEX2 cleavage sequence (see abbreviations in the text).

of ~3.5–4.5) showed quick decay due to proteolysis that proceeded significantly faster at room temperature (RT).

Two strategies were employed to minimize proteolysis in this system. Proteolytic activity of native fungal proteases is mainly neutralized by keeping the pH above 7. Secondly, a strain of *A. niger* more deficient in proteases, non-acidifying mutant D15#26 was used (instead of AB4-1).




Figure 2

SDS-PAGE analyses of proteolytic digestion. 1 – protein ladder; 2 and 11 – α_1 -PI standard; 3 – α_1 -PI standard kept O/N at RT; 4 – Supernatant (S) from 5 days growth of *A. niger* AB4-1; 5 – α_1 -PI + S (initial, pH 3.5) O/N, RT; 6 – α_1 -PI + S (initial, pH 3.5) O/N, 4°C; 7 – α_1 -PI + S pH 7.3 kept O/N at RT; 8 – α_1 -PI + S pH 7.3 kept O/N at 4°C; 9 – α_1 -PI + S pH 8.4 kept O/N at RT; 10 – α_1 -PI + S pH 8.4 kept O/N at 4°C. The initial concentration of α_1 -PI standard in all samples was 5.175 mg/mL.

3. Analyses of the expression of α_1 -PI in *A. niger*

The results reported here utilize the D15#26 strain and pH above 7.0, as indicated above. The supernatant samples from the cultures were assayed by ELISA. In addition, to minimize the possibility of false interpretation of the ELISA results, SDS-PAGE and Western blot analysis were used, since it was shown by us that the ELISA can detect peptides derived from digestion of α_1 -PI [21]. Fig. 3 shows a typical SDS-PAGE and complimentary Western blot for the supernatant of the selected D15#26 transformant taken after 96 hours of growth (lanes 3–5). Lanes 6–9 corresponds to another D15#26 selected transformant. The yields estimated by ELISA and by Western blot were in agreement indicating secretion of up to 12 mg/L of the target protein. The r- α_1 -PI was shown to be functionally active (see below). No cytoplasmic accumulation was detected in the control analysis of the *A. niger* cell extract.

4. Characterization of r- α_1 -PI from *A. niger*

Fig. 4 compares r- α_1 -PI from *A. niger* with standard pd- α_1 -PI, enzymatically deglycosylated pd- α_1 -PI (de-pd- α_1 -PI), and with r- α_1 -PI from *E. coli*. Unlike r- α_1 -PI in the soluble protein fraction from *E. coli* (see SDS-PAGE in [21]), the raw supernatant from *A. niger* has a relatively simple protein composition.

4.1. HPLC analyses

Size-exclusion (SE) HPLC data was used for the stability evaluation of the r- α_1 -PI's. The fractions corresponding to the α_1 -PI peak with a retention time of 21 min were collected and stored on ice. It is noteworthy that the retention times of r- α_1 -PI's from *A. niger* and from *E. coli* are essentially the same as that of pd- α_1 -PI (~21 minutes in the conditions used). Fig. 5 demonstrates that whereas the non-glycosylated r- α_1 -PI from *E. coli* (dashed trace) undergoes rapid aggregation (as observed by accumulation of the peak with a retention time of ~13 min corresponding to polymerized α_1 -PI, gray trace), the




Figure 3
 SDS-PAGE and Western blot (right panel) analysis of α_1 -PI expression in *A. niger* D15#26. 1-protein ladder, 2 and 10 - pd- α_1 -PI standard, 3-5 - supernatant from growth of the transformant #1 (30, 20, and 10 μ L respectively), 6 – supernatant from growth of PYRG-transformant, 7-9 - supernatant from growth of the transformant #2 (the 30, 20, and 10 μ L respectively).




Figure 4
 SDS-PAGE and Western blot (right panel) comparison of different α_1 -PI's: 1- protein ladder; 2 and 6 - pd- α_1 -PI standard; 3 - deglycosylated pd- α_1 -PI; 4 - α_1 -PI from *E. coli* (eluted from TALON beads); 5 - r- α_1 -PI in the supernatant from *A. niger* D15#26.




Figure 5

Evaluation of stability of r- α_1 -PI from *A. niger* (solid trace) and from *E. coli* (dashed trace) by SE-HPLC. The fractions of r- α_1 -PI were collected by HPLC, kept on ice and re-injected. The gray dashed trace reflects polymerization of r- α_1 -PI from *E. coli* as shown 1.5 h later after elution, while no aggregation was observed for r- α_1 -PI from *A. niger* for ~12 hours; all analytes were stored at 4°C.

glycosylated r- α_1 -PI from the *A. niger* supernatant (solid trace) is relatively stable during at least 12 hours.

4.2. Evaluation of molecular mass

The molecular mass sizes of r- α_1 -PI's were evaluated by SDS-PAGE and Western blot analysis, using pd- α_1 -PI and its deglycosylated version as the references (Fig. 4). In addition, we performed mass-spectrometric analysis of the proteins using MALDI-MS in the conditions established earlier [22]. α_1 -PI is a heterogeneous protein due to intrinsic carbohydrate diversity and some differences in the polypeptide part [23-26]. Therefore, in the MALDI-MS spectra the molecular ion and the related ions are represented by its ion distribution clusters, and the molecular mass values are assigned by the major ion peak at which the cluster is centered. The molecular weight of the standard pd- α_1 -PI (spectra not shown) is determined by the observed molecular ion [M+H]⁺ at 50,300 Da (Table 1), which is in agreement with its half-mass ion [M/2+H]⁺ detected at 25,150 Da. Mass spectrum of r- α_1 -PI from *A.*

niger shows the molecular ion cluster centered at 50,130 Da, which is close to that of plasma α_1 -PI standard. Therefore, these results allow for more accurate molecular mass values and suggest that there is no "hyperglycosylation" in case of r- α_1 -PI secreted from *A. niger*. Enzymatically deglycosylated pd- α_1 -PI showed the main molecular ion at 44,210 Da, therefore, serving as an additional non-glycosylated reference.

4.3. Activity of r- α_1 -PI

Inhibitory activity of the recombinant α_1 -PI secreted into the supernatant was evaluated against porcine pancreatic trypsin, using pd- α_1 -PI as a standard (assigned as 100%, Table 1). The α_1 -PI assay samples were adjusted to the same initial concentration and subjected to the same dilutions on the plate. Basal (low) response of the supernatant from the growth of D15#26 transformed with PyrG only was subtracted. Activity of the r- α_1 -PI from *A. niger* was not less than 75% of the standard (*e.g.*, to inhibit 0.7 μ mole active PPT about 0.92 μ mole of r- α_1 -PI was

Table 1: Activity of r- α_1 -PI from *E. coli* and *A. niger* and evaluation of molecular weight of recombinant and plasma-derived species determined by MALDI-MS

Protein	Activity ^a (%)	Molecular mass ^b
pd- α_1 -PI (standard)	100	50,300
degly-pd- α_1 -PI	n.a. ^c	44,210
r- α_1 -PI/ <i>E. coli</i>	35 ^d	45,000 ^e
r- α_1 -PI/ <i>A. niger</i>	76 ^{f,g}	50,100

^aThe calculations were based on comparison with pd α_x tPI as a standard (100%) and using normalized equal concentrations of r- α_1 -PI samples as determined by ELISA; ^bmolecular weight is shown as an average value measured for 2 samples; ^c not available; pd- α_1 -PI was enzymatically deglycosylated under denaturing conditions; ^d as measured for His-tagged r- α_1 -PI within 1.5 h after elution from the TALON beads; ^e as estimated by amino acid sequence for α_1 -PI without glycans; ^f shown for *A. niger* supernatant after Amicon 10 K filtration procedure; ^g the standard deviation of our potency assay is \pm 15%.

required). This activity was significantly higher than that of r- α_1 -PI from *E. coli* (~35%). The latter correlates well with the fact that non-glycosylated r- α_1 -PI from *E. coli* tends to aggregate rapidly with subsequent loss of activity.

Discussion

In this paper we demonstrate that it is possible to express the human gene for α_1 -PI in the filamentous fungus *A. niger* as a secreted glycosylated protein with stability that is significantly improved in comparison with non-glycosylated recombinant protein from *E. coli*. The secreted r- α_1 -PI was characterized in comparison with pd- α_1 -PI and its enzymatically deglycosylated version (de-pd- α_1 -PI) used as the "in-house" standards, as well as with non-glycosylated r- α_1 -PI produced in *E. coli* [27].

A. niger strains have been already used as hosts for the production of other serine proteinase inhibitors. Mikosch et al. reported on the secretion of active human mucus proteinase inhibitor (antileukoproteinase), which is a 11.7 kDa non-glycosylated single chain protein stabilized by eight disulfide bonds [16]. Later, MacKenzie et al. reported on an aberrant processing of bovine pancreatic trypsin inhibitor (known as aprotinin, a small polypeptide of 58 amino acid residues) secreted by *A. niger* [20]. However, to the best of our knowledge, our work shows for the first time that human α_1 -PI, a complex glycoprotein of medium size (394 amino acid residues, ~50.3 kDa) and of significant therapeutic value, can be successfully produced in this system.

The expression of α_1 -PI in *A. niger* was designed to obtain the recombinant inhibitor in the secreted glycosylated form with enhanced yield. This was successfully achieved by fusion of the α_1 -PI coding sequence downstream of the glucoamylase truncated gene (*glaA_{C2}*), under transcriptional control of the constitutively expressed glyceraldehyde-3-phosphate dehydrogenase (*gpdA*) promoter, according to the earlier established strategy [14-16]. The efficiency of protein production was evaluated by the level of expression by direct determination of the secreted r- α_1 -PI in the supernatant during growth.

To minimize possible interactions of native fungal proteases with the target recombinant inhibitor during growth, the following changes were implemented: (a) a protease-deficient mutant D15#26 was used for transformation (instead of AB4-1), and (b) the pH of the supernatants was maintained above 7.0. Screening for the target protein was routinely assayed by ELISA, in a protocol recently developed by us for this purpose [21]. However, given the subtle nature of α_1 -PI and the challenge of producing this medium size inhibitor in its biologically active form, standard SDS-PAGE/Western blot analysis was also conducted to visualize evidence for degradation peptides.

As an analytical tool, ELISA was utilized to quantify r- α_1 -PI's production under various growth conditions. Maximum yields of r- α_1 -PI achieved in shake-flask cultures were at 12 mg/L, after 96 hours of batch culture growth, which is comparable with those reported for other mammalian proteins (10 mg/L) that were obtained in *Aspergillus* strains [16,17,28]. Although these yields of r- α_1 -PI appear to be lower than the yields we achieved in *E. coli* (20 mg/L and 38 mg/L in raw extracts before purification), the protein obtained from *A. niger* is significantly more stable than the non-glycosylated α_1 -PI versions from *E. coli*, as evaluated by SE-HPLC.

Furthermore, inhibitory activity of r- α_1 -PI from *A. niger* is significantly higher than that of non-glycosylated r- α_1 -PI version from *E. coli*, which tends to aggregate more rapidly, thereby losing its inhibitory activity. This is consistent with the previously reported data on activity and stability of r- α_1 -PI's that were produced in other host systems [8], thus confirming that low stability results in lower potency.

As was reported earlier for bovine pancreatic trypsin inhibitor [20], the possibility for aberrant processing of the fusion protein by KEX2-like endoprotease may result in a mixture of target proteins differing at the N-terminus. Although this possibility was not evaluated for r- α_1 -PI obtained from shake-flask cultures, the secreted r- α_1 -PI had high inhibitory activity (not less than 75%) in this system, suggesting that r- α_1 -PI was mostly processed correctly. Although a higher yield was mentioned for r- α_1 -PI produced in a fermentor [8], it related to a total r- α_1 -PI that contained certain amounts of latent (inactive) and digested α_1 -PI species. The optimization for a semi-large scale production of r- α_1 -PI in a fermentor with all parameters controlled is currently under development [29].

As the secreted protein, r- α_1 -PI is glycosylated, and the SDS-PAGE and Western blot demonstrate that the electrophoretic mobility of r- α_1 -PI from *A. niger* is comparable with that of pd- α_1 -PI standard. Together with the activity results and SE-HPLC data, it suggests a correct cleavage by KEX2-like site and an appropriate folding of the secreted protein. MALDI-MS data provide additional proof that the average molecular mass of the recombinant protein (~50,100 Da) is close to that observed for pd- α_1 -PI (50,300 Da), and therefore, the sizes of glycans in both are comparable. Although the results of testing with PNGase F suggest that glycosylation is predominantly of N-type, more detailed glycan characterization could be of interest in view of the comprehensive glyco-proteomic analysis recently performed by Kolarich et al. [25,26] for native human α_1 -PI.

Conclusion

As a part of our multi-step investigation of α_1 -PI, we have successfully expressed the human gene for α_1 -PI in the filamentous fungus *Aspergillus niger*, as a fusion protein with glucoamylase G2, a strongly expressed secreted leader protein, separated by a processing peptide sequence to allow *in vivo* cleavage. SDS-PAGE, Western blot, ELISA and inhibitory activity assays enabled us to select the transformant(s) that were capable of secreting biologically active glycosylated r- α_1 -PI with improved stability and with yields of up to 12 mg/L. MALDI-MS analysis further confirmed that molecular mass of the r- α_1 -PI was similar to that of native plasma protein, thus suggesting that there was no "hyperglycosylation" from the host. Taken together, the results of our shake-flask experiments suggest the feasibility of this system for further development of r- α_1 -PI, a protein of our particular therapeutic interest.

Methods

1. α_1 -PI references, reagents and solutions

α_1 -PI from CalBiochem (Darmstadt, Germany) was used as an "in-house" α_1 -PI standard which was qualified as earlier described [21]. The concentrations of the purified α_1 -PI preparations were determined spectrophotometrically using a coefficient of extinction $A_{280}^{0.1\%}$ 0.433 [30]. Deglycosylated and non-glycosylated α_1 -PI reference samples were prepared as described below. Bovine serum albumin, trypsin from porcine pancreas, *p*-nitrophenyl *p*'-guanidino-benzoate hydrochloride (NPGb), *N*-benzoyl-L-arginine *p*-nitroanalide hydrochloride (BAPNA), 2-mercaptoethanol, anhydrous dibasic sodium phosphate, 3,3',5,5'-tetra-methylbenzidine (TMB) liquid substrate system for membrane and TMB for ELISA, isopropyl β -D-1-thiogalacto-pyranoside (IPTG), PNGase F and sinapinic acid were from Sigma Chemical Co. (St. Louis, MO). Hexafluoroisopropanol was from Brand-Nu Laboratories (Meriden, CT). Cellulase was from Interspex Product (San Mateo, CA). Phosphate buffered saline (D-PBS) without Ca & Mg was from Quality Biological, Inc., (Gaithersburg, MD). Simply Blue™ SafeStain and SeeBlue Plus2® Pre-Stained Standard were from Invitrogen (Carlsbad, CA). All other chemicals were ACS reagent grade from Fisher Scientific (Pittsburgh, PA). Antibodies for Western blot: goat anti-human α_1 -PI affinity purified and rabbit anti-goat alkaline phosphatase (AP) conjugate were from Jackson ImmunoResearch Laboratories (West Grove, PA). AP Conjugate Substrate Kit to visualize the alkaline phosphatase in Western blot was from Bio-Rad Laboratories (Hercules, CA). Antibody for ELISA: rabbit anti-human α_1 -PI (capture antibody) from Sigma Chemical Co. (St. Louis, MO) and sheep anti-human α_1 -PI-HRP (antibody-enzyme conjugate) from BioDesign International (Saco, ME).

2. Strains

Aspergillus niger (pyrG-) strains AB4-1 (parental) and D15#26, a protease-deficient, non-acidifying mutant [31] from TNO were used for transformation and production of glycosylated r- α_1 -PI. *E. coli* strain TOP10 used for construction and propagation of vectors was from Invitrogen Co. (Carlsbad, CA). *E. coli* strain JM109 used for cDNA preparation was from Promega Co. (Madison, WI).

3. Culture conditions

For selection of the *A. niger* transformants, the following selective solid minimal uridine-deficient medium was used containing (per 1 liter): 5.95 g NaNO₃, 0.52 g KCl, 1.5 g KH₂PO₄, 0.24 g MgSO₄, 1% (wt/vol) glucose, and trace elements (1,000 × stock: 12.27 g ZnSO₄, 3.15 g MnCl₂, 5.0 g FeSO₄ × 7H₂O, 0.92 g CoCl₂, 1.02 g CuSO₄, 1.28 g Na₂MoO₄, 50.8 g EDTA).

The biomass for protoplasting and transformation was obtained by growing in the complete media that contained (per 1 liter): 6 g NaNO₃, 0.52 g KCl, 0.68 g KH₂PO₄, 1.045 g K₂HPO₄, 2.77 g MgSO₄ × 7 H₂O, 1 g yeast extract, 1 g casamino acids, 10 g glucose, 1 ml vitamins solution (per 100 ml: 0.01 g pyridoxine-HCl, 0.015 g thiamine-HCl, 0.075 g *p*-aminobenzoic acid, 0.25 g nicotinic acid, 0.25 g riboflavin, 2.0 g choline-HCl, 0.005 g biotin), 1 ml trace solution (per 100 ml: 2.2 g ZnSO₄, 1.1 g H₃BO₃, 0.5 g MnCl₂ × 4 H₂O, 0.5 g FeSO₄ × 7 H₂O, 0.16 g CoCl₂ × 6 H₂O, 0.16 g CuSO₄, 0.11 g (NH₄)₂MoO₄, 6.5 g EDTA tetrasodium salt) supplemented with 10 mM of uridine.

4. DNA and plasmids

The gene for human α_1 -PI was kindly provided by Dr. Sanio Woo (Mount Sinai, NY, NY). The pAN56-1 vector and PyrG selection plasmid were from Dyadic Nederland BV.

5. Construction of expression plasmid

The expression vector pAN56-1/ α_1 -PI (Figure 1) was constructed using established molecular methods protocols [32]. A full length 1230 bp cDNA encoding the mature human α_1 -PI (GenBank Accession # [K01396](#)) was generated by PCR flanked by BstB1 restriction sites and linked with nucleotide sequence encoding a dibasic processing site (N-V-I-S-K-R). The following primers were used: (1) 5' TTCGAATGTGATATCCAAGCGCGGAGATCCCCAG-GGAGATGCTGCC containing a processing sequence (underlined), and (2) 3' TTCGAATTATTTTGGGTGGGATTCACCACITTTCCCATGAAGAGGGGTGGG. PCR was performed using Model PTC-200 of Peltier Thermal Cycler (MJ Research, Inc.). The PCR fragment was then ligated into the plasmid pCR2.1 TOPO (Invitrogen Co., Carlsbad, CA) and the sequence of the amplification product was confirmed by sequencing at the CBER FDA core facilities. Excising the

fragment by BstB1 allows the subcloning into the NarI digested expression vector pAN56-1 (from TNO, GenBank Accession # Z32700) to generate pAN56-1/ α_1 -PI. The cloning resulted in expression cassette that contained the constitutively expressed glyceraldehydes-3-phosphate dehydrogenase promoter (P_{gpdA}), gene for mature human α_1 -PI fused to the coding region of glucoamylase truncated gene (GLA) linked by the processing site, followed by the trpC terminator (T_{trpC}).

6. Transformation and selection of *A. niger* transformants

The *A. niger* strain D15#26 was grown in minimal media (above) for 16 h at 30°C with shaking at 150 rpm. The protoplasts preparation and transformation was followed as described in [33] with the exception of using 5 mg of cellulase per mL of wet mycelia instead of NovoZym 234. The protoplasts were co-transformed with the expression vector pAN56-1/ α_1 -PI and PyrG selection plasmid. PyrG transformants were selected on plates of solid minimal media without uridine, prepared with 15 g/L Oxoid agar. The plates were incubated at 30°C for 2 days until fungal colonies became visible. Large colonies were selected and subsequently transferred onto new plates prior to screening for α_1 -PI production in minimal liquid media.

7. Screening for α_1 -PI producers by SDS-PAGE and Western blot

The selected PyrG transformants were screened for the appearance of r- α_1 -PI in the supernatants during growth (200 mL per 1000 mL flask at 28°C on rotary shaker at 150 rpm and incubated for 5 days; pH was maintained above 7.0 by using 2 M NaOH solution). The aliquots of the supernatants were collected during the 5 days growth and analyzed for the presence of secreted r- α_1 -PI by SDS-PAGE and Western blot analysis using pre-cast 7.5% and 4–20% Tris/Glyc mini-gels under reducing conditions. Simply Blue™ SafeStain was used for staining, and SeeBlue Plus2® Pre-Stained Standard served as the protein ladder. Goat anti-human α_1 -PI affinity purified and rabbit anti-goat alkaline phosphatase (AP) conjugate followed by detection with AP Conjugate Substrate Kit were used in the Western blot to visualize the protein. Based on the screening, the best transformant was selected for further studies.

8. Quantification of r- α_1 -PI by ELISA

Quantification of r- α_1 -PI in raw biological samples was performed as in [21]. The samples were assayed *in triplicate*. Spiking with the supernatant aliquots adjusted to pH 7.3 and 8.4 have been conducted similarly. The blank supernatant from growth of *A. niger* transformed with PyrG plasmid only, was used as a matrix to confirm the specificity of the antigenic determination.

9. Evaluation of α_1 -PI proteolytic digestion by fungal proteases

To evaluate for possible proteolytic degradation of r- α_1 -PI during growth, the standard pd- α_1 -PI was diluted to 5.175 mg/mL by adding Tris buffer or *A. niger* supernatant from the strain D15#26. The samples (in Tris and in supernatant) were incubated at 4°C and at RT for overnight (O/N), and evaluated by ELISA according to the protocol earlier described [21].

10. SE-HPLC

SE-HPLC analysis was carried out on the System Gold® HPLC (Beckmann Corp.) controlled by 32 Karat Work station software. The stationary phase: two TosoHaas TSK-3000SW_{XL} columns (5 μm , 7.8 mm \times 30 cm) connected in series and an SW_{XL} guard column. The mobile phase: PBS buffer, pH 7.4. The flow rate: 1 mL/min. Detection: absorbance at 280 and 215 nm.

11. Activity assay

The inhibitory activities of r- α_1 -PI's produced in *A. niger* and in *E. coli* were evaluated against trypsin from porcine pancreas. Titration of trypsin active sites was performed using NPGb as an active-site titrant according to the established procedure [34]. Our plate-based version of this assay reproducibly showed 76% of the active sites in the porcine pancreatic trypsin. Determination of the inhibitory activity of α_1 -PI is based on measuring the residual assay protease activity after trypsin interaction with various amounts of α_1 -PI. The inhibitory activity of r- α_1 -PI was determined in comparison with an in-house standard (100%) and using BApNA as a chromogenic substrate. The residual trypsin activity was measured by monitoring the absorbance of the released *p*-nitroanilide at 405 nm (molar extinction coefficient of 10,500 M⁻¹cm⁻¹).

The samples of r- α_1 -PIs from *A. niger* and *E. coli* were prepared for assaying inhibitory activity as follows. (a) r- α_1 -PI from *E. coli*. Soluble cytosolic protein fractions from *E. coli* biomass were subjected to purification on TALON beads, the eluted fractions containing r- α_1 -PI were collected and concentrated using Amicon (10 K) filtration at 13,000 rpm; the concentrate was analyzed by SE-HPLC, and the fraction eluted at 21 min was collected and placed on ice. The r- α_1 -PI concentration was determined spectrophotometrically, and its activity was immediately assayed. (b) Inhibitory activity of r- α_1 -PI from *A. niger* transformants was evaluated as follows. The supernatants (pH 7.0) were concentrated and desalted by aid of filtration on Amicon 10 K and kept on ice before use the same day. Samples in 1 mL aliquots were mixed with equal volume of Tris buffer, pH 8.4, and cleared by centrifugation at 24,000 rpm for ~5 min. The r- α_1 -PI concentration was determined by ELISA as described above. Trypsin solution in Tris buffer served as a control protease sample. After

mixing with the samples containing standard α_1 -PI and r- α_1 -PI samples, the mixtures were incubated for 15 min at RT. After adding 100 μ L of the substrate solution, simultaneously by using a multi-channel pipette, the residual trypsin activity was immediately monitored as end point kinetics at 405 nm on THERMOmax™ microplate reader (Molecular Devices Co., Menlo Park, CA).

Trypsin active site titration and the inhibitory assay were performed in duplicate at 25°C in Tris buffer (pH 8.4). Back calculations for activities of r- α_1 -PIs in the original samples were performed using the corresponding dilution factors.

12. MALDI-MS

A linear time-of-flight instrument with delayed extraction (Voyager-DE, Applied Biosystems, Framingham, MA) was used. Mass calibration was performed using bovine serum albumin (66,500 Da) as an internal standard. The average of 50–200 laser shots was used for recording the mass spectra within the acquisition mass range of 15,000 – 80,000 Da. The samples were prepared as described in [22] with minor changes as following. The samples (1 μ L of supernatants containing α_1 -PI or standard pd- α_1 -PI) were loaded onto a gold-plated sample plate and allowed to air dry. The matrix solution was prepared by mixing 12 μ g of sinapinic acid with 300 μ L of 0.1% trifluoroacetic acid/acetonitrile (1:1, v/v). After spinning down at 5,000 rpm, 1 μ L of the resulting solution was loaded on the top of each spot of the sample and allowed to air dry prior to measurement of the mass spectra.

13. Deglycosylated α_1 -PI reference

De-pd- α_1 -PI was obtained from pd- α_1 -PI by enzymatic deglycosylation using PNGase F according to the procedure described elsewhere [35]. The de-pd- α_1 -PI was diluted with water to concentration 0.2 μ g/ μ L followed by 1:1 (v/v) dilution with Laemmli buffer, boiled for 3 min and stored (aliquoted) at -20°C until use.

14. Non-glycosylated r- α_1 -PI reference produced in E. coli

Expression of the human gene for α_1 -PI in *E. coli* special strain BL21(DE3)pLysS (Novagen) was performed as a 9-His-tagged protein as reported earlier [27]. Briefly, the human gene for α_1 -PI was cloned into the pET-19b vector. The expression vector ET-19b, PCR II TOPO vector, TOPO TA Cloning Kit and the restriction enzymes were from (Novagen). After transformation, the host cells Rosetta(DE3)pLysS containing the pET-19b/ α_1 -PI construct were grown overnight at 37°C and 250 rpm in LB media containing Ampicillin (100 μ g/mL) to a density of 0.8–0.9 OD read at 600 nm (OD₆₀₀). After inoculation (1:100), a culture of LB-medium supplemented with ampicillin (100 μ g/mL) was grown (37°C, at 250 rpm) to an OD₆₀₀ of 0.5, and the expression was induced by add-

ing 1.0 mM IPTG. The growth was continued for another 3 h (37°C, 250 rpm) to OD₆₀₀ of 1.1–1.3. The cells were harvested by centrifugation (15 min, 5,000 rpm, 4°C), and washed twice with PBS buffer, pH 7.4, by resuspending and centrifugation. The washed cells were lysed, and the soluble fraction was used for the r- α_1 -PI purification on TALON beads. (Blank culture with pET-19B vector without α_1 -PI gene was performed in a similar manner, and the supernatant served as a control to assure the specificity of α_1 -PI quantification by ELISA and potency measurements.)

List of abbreviations

α_1 -PI, α_1 -proteinase inhibitor; r- α_1 -PI, recombinant α_1 -PI; *A. niger*, *Aspergillus niger*; AP, alkaline phosphatase; BApNA, *N*-benzoyl-L-arginine *p*-nitroanalide hydrochloride; de-pd- α_1 -PI, deglycosylated pd- α_1 -PI; ELISA, Enzyme-Linked ImmunoSorbent Assay; glaA, glucoamylase A; HRP, horse radish peroxidase; IPTG, isopropyl β -D-1-thiogalacto-pyranoside; MALDI-MS, matrix-assisted laser desorption/ionization mass spectrometry; NPGb, *p*-nitrophenyl *p*'-guanidino-benzoate hydrochloride; pd-, plasma-derived; RT, room temperature; SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis; SE-HPLC, size-exclusion high-performance liquid chromatography; serpin, serine protease inhibitor; U, uridine.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

EK and YO initiated the project. EK performed biochemical and analytical protein characterization and drafted the manuscript. YO did all molecular construction and DNA analysis. LT carried out the transformation and ran the shake-flask growth. ND assisted in initial transformant selection and screening. EK, YO, YS, BG and PP participated in design and coordination of experiments. PP provided strains and molecular tools, and shared his expertise by consulting.

All authors read and approved the final version of the manuscript.

Acknowledgements

The authors are grateful to Dr. Sanio Woo (Mount Sinai, NY, NY) for the generous gift of cDNA for human α_1 -PI and to Drs. Abdu Alayash and Dominador Manalo for valuable discussions and critical reading of the manuscript. The opinions and assertions herein are the scientific views of the authors and are not to be construed as policy of the United States Food and Drug Administration, National Institutes of Health, or the United States Department of Health and Human Services.

References

- Devlin GL, Bottomley SP: **A protein family under "stress" – serpin stability, folding and misfolding.** *Front Biosc* 2005, **10**:288-299.
- Lomas DA: **Molecular mousetraps, α_1 -antitrypsin deficiency and the serpinopathies.** *Clin Med* 2005, **5**:249-257.
- Huntington JA: **Shape-shifting serpins – advantages of a mobile mechanism.** *Trends Biochem Sc* 2005, **31**:427-435.
- Whisstock JC, Bottomley SP: **Molecular gymnastics: serpin structure, folding and misfolding.** *Curr Opin Struct Biol* 2006, **16**:761-768.
- Brantly ML, Wittes JT, Vogelmeier CF, Hubbard RC, Fells GA, Crystal RG: **Use of highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes.** *Chest* 1991, **100**:703-708.
- Crystal RG: **The alpha 1-antitrypsin gene and its deficiency states.** *Trends Genet* 1989, **5**:411-417.
- Crystal R: *Alpha 1-Antitrypsin Deficiency* Edited by: R. Crystal. Marcel Dekker, Inc; 1996.
- Karnaukhova E, Ophir Y, Golding B: **Recombinant human alpha-I-proteinase inhibitor towards therapeutic use.** *Amino Acids* 2006, **30**:317-332.
- Maras M, van Die I, Contreras R, van den Hondel CAMJJ: **Filamentous fungi as production organisms for glycoproteins of biomedical interest.** *Glycoconj J* 1999, **16**:99-107.
- Gerngross TU: **Advances in the production of human therapeutic proteins yeasts and filamentous fungi.** *Nature Biotechnol* 2004, **22**:1409-1414.
- Nevalainen KMH, Te'o VS, Bergquist PL: **Heterologous protein expression in filamentous fungi.** *Trends Biotechnol* 2005, **23**:468-474.
- Punt PJ, van Biezen N, Conesa A, Albers A, Mangnus J, van den Hondel CAMJJ: **Filamentous fungi as cell factories for heterologous protein production.** *Trends Biotechnol* 2002, **20**:200-206.
- Ward M, Lin C, Victoria DC, Fox BP, Fox JA, Wong DL, Meerman HJ, Pucci JP, Fong RB, Heng MH, Tsurushita N, Gieswein C, Park M, Wang H: **Characterization of humanized antibodies secreted by *Aspergillus niger*.** *Appl Environ Microbiol* 2004, **70**:2567-2576.
- Ward M, Wilson LJ, Kodama KH, Rey MVV, Berka RM: **Improved production of chymosin in *Aspergillus* by expression as a glucoamylase-chymosin fusion.** *Bio/Technology* 1990, **8**:435-440.
- Ward M, Wilson LJ, Kodama KH: **Use of *Aspergillus* overproducing mutants, cured of integrated plasmid, to overproduce heterologous proteins.** *Appl Microbiol Biotechnol* 1993, **39**:738-743.
- Mikosch T, Klemm P, Gassen HG, van den Hondel CAMJJ, Kemme M: **Secretion of active human mucus proteinase inhibitor by *Aspergillus niger* after KEX2-like processing of a glucoamylase-inhibitor fusion protein.** *J Biotechnol* 1996, **52**:97-106.
- Contreras R, Carrez D, Kinghorn JR, van den Hondel CAMJJ, Fiers W: **Efficient KEX2-like processing of a glucoamylase-interleukin-6 fusion protein by *Aspergillus nidulans* and secretion of mature interleukin-6.** *Biotechnology (NY)* 1991, **9**:378-381.
- Archer DB, Jeenes DJ, MacKenzie DA: **Strategies for improving heterologous protein production from filamentous fungi.** *Antonie Van Leeuwen* 1994, **65**:245-250.
- Gouka RJ, Punt PJ, van den Hondel CAMJJ: **Efficient production of secreted proteins by *Aspergillus*: progress, limitations and prospects.** *Appl Microbiol Biotechnol* 1997, **47**:1-11.
- MacKenzie DA, Kraunsoe JAE, Chesshyre JA, Lowe G, Komiyama T, Fuller RS, Archer DB: **Aberrant processing of wild-type and mutant bovine pancreatic trypsin inhibitor secreted by *Aspergillus niger*.** *J Biotechnol* 1998, **63**:137-146.
- Karnaukhova E, Golding B, Ophir Y: **Development and evaluation of an ELISA for quantification of human α_1 -proteinase inhibitor in complex biological mixtures.** *Biologicals* 2007, **35**:285-95.
- Karnaukhova E, Schey K, Crouch RK: **Circular dichroism and cross-linking studies of bacteriorhodopsin mutants.** *Amino Acids* 2006, **30**:17-23.
- Mega T, Lujan E, Yoshida A: **Studies on the oligosaccharide chains of human alpha 1-protease inhibitor: II. Structure of oligosaccharides.** *J Biol Chem* 1980, **255**:4057-4061.
- Travis J, Salvesen GS: **Human plasma proteinase inhibitors.** *Annu Rev Biochem* 1983, **52**:655-709.
- Kolarich D, Weber A, Turecek PL, Schwarz HP, Altmann F: **Comprehensive glyco-proteomic analysis of human α_1 -antitrypsin and its charge isoforms.** *Proteomics* 2006, **6**:3369-3380.
- Kolarich D, Turecek PL, Weber A, Mitterer A, Graninger M, Matthiessen P, Nicolaes GAF, Altmann F, Schwarz HP: **Biochemical, molecular characterization, and glycoproteomic analyses of α_1 -proteinase inhibitor products used for replacement therapy.** *Transfusion* 2006, **46**:1959-1977.
- Karnaukhova E, Ophir Y, Golding B, Shrake A: **Recombinant human alpha-I-proteinase inhibitor: glycosylation, stability and biological activity.** In *Abstracts of 10th FDA Science Forum, B-18* Washington DC:47. May 18-19, 2004
- Roberts IN, Jeenes DJ, MacKenzie DA, Wilkinson AP, Sumner IG, Archer DB: **Heterologous gene expression in *Aspergillus niger*: a glucoamylase-porcine pancreatic phospholipase A2 fusion protein is secreted and processed to yield mature enzyme.** *Gene* 1992, **122**:155-61.
- Chill L, Loc B, Karnaukhova E, Ophir Y, Golding B, Shiloach J: **Production of human α I-proteinase inhibitor from *Aspergillus niger*.** *4th Recombinant Protein Production Meeting, a Comparative View on Host Physiology. Barcelona, September 21-23, 2006. Microb Cell Factories* 2006, **5**(Suppl 1):P62.
- Edelhoch H: **Spectroscopic determination of tryptophan and tyrosine in proteins.** *Biochemistry* 1967, **6**:1948-1954.
- Gordon CL, Khalaj V, Ram AFJ, Archer DB, Brookman JL, Trinci APJ, Jeenes DJ, Doonan JH, Wells B, Punt PJ, van den Hondel CAMJJ, Robson GD: **Glucoamylase::green fluorescent protein fusion to monitor protein secretion in *Aspergillus niger*.** *Microbiol* 2000, **146**:415-426.
- Sambrook J, Fritsch EF, Maniatis T: *Molecular Cloning: A Laboratory Manual* Cold Spring Harbor Laboratory Press; 1989.
- Punt PJ, van den Hondel CAMJJ: **Transformation of filamentous fungi based on hygromycin B and phleomycin resistance markers.** *Methods Enzymol* 1992, **216**:447-457.
- Chase T, Shaw E: **p-Nitrophenyl-p'-guanidino benzoate HCl: a new active site titrant for trypsin.** *Biochem Biophys Res Commun* 1967, **29**:508-514.
- Tarentino AL, Gomez CM, Plummer TH Jr: **Deglycosylation of asparagine-linked glycans by peptide:N-glycosidase F.** *Biochemistry* 1985, **24**:4665-4671.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

